“Panel Discussion: Treatment Options for Relapsed Refractory Diffuse Large B-Cell Lymphoma (R R DLBCL) Patients”. Canadian Hematology Today, vol. 1, no. S10, Oct. 2022, https://doi.org/10.58931/cht.2022.1S1029.